Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir and Low-dose Gemcitabine in EBV-associated Gastric Cancer
NCT05431244Withdrawn
- Sponsor
- Samsung Medical Center
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
Open-label trial of valganciclovir in gastric adenocarcinoma, sponsored by Samsung Medical Center. Primary endpoint: Objective Response Rate at 24 months. Planned start Jul 2022; status: withdrawn.
02
Drugs
valganciclovir
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT05431244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05431244.